← Back to Search

Monoclonal Antibodies

BeCare application for Multiple Sclerosis

N/A
Waitlist Available
Led By Laura Tabacof, MD
Research Sponsored by Icahn School of Medicine at Mount Sinai
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up week 24-32
Awards & highlights

Study Summary

This trial will use the BeCare app to study how well Natalizumab works in people with RRMS.

Eligible Conditions
  • Multiple Sclerosis

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~week 24-32
This trial's timeline: 3 weeks for screening, Varies for treatment, and week 24-32 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
The Expanded Disability Status Scale (EDSS)
Secondary outcome measures
Application Based - Arm elevation test
Application Based - Coded Message Cognitive Test
Application Based - Contrast sensitivity test
+16 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: BeCare applicationExperimental Treatment1 Intervention
individuals with relapsing-remitting MS (RRMS) on Natalizumab therapy

Find a Location

Who is running the clinical trial?

Icahn School of Medicine at Mount SinaiLead Sponsor
860 Previous Clinical Trials
524,476 Total Patients Enrolled
8 Trials studying Multiple Sclerosis
515 Patients Enrolled for Multiple Sclerosis
Laura Tabacof, MDPrincipal InvestigatorIcahn School of Medicine at Mount Sinai
1 Previous Clinical Trials
11 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Who else is applying?

What state do they live in?
New York
How old are they?
18 - 65
What site did they apply to?
Mount Sinai Hospital
What portion of applicants met pre-screening criteria?
Met criteria

How responsive is this trial?

Typically responds via
Email
Most responsive sites:
  1. Mount Sinai Hospital: < 48 hours
Average response time
  • < 2 Days
Recent research and studies
clinicaltrials.govStudy
Sensation, Motion, and Quality of Life on Natalizumab and Off Natalizumab
Laura Tabacof 2022. "Sensation, Motion, and Quality of Life on Natalizumab and Off Natalizumab". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05172466.
~0 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top